FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. PMID 41579900 · Lancet Neurol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea® in Patients with Wet Age-Related Macular Degeneration. PMID 41578078 · Ophthalmol Ther · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer. PMID 41561488 · Eur Urol Open Sci · 2026-Feb The report is an original article about a Phase III randomized trial in metastatic prostate cancer. However, it is not eligible because: 1) The intervention is exercise-based, not a drug-containing intervention. 2) The primary efficacy outcomes (survival) are explicitly stated to be reported separately; this paper only reports feasibility and implementation. There is no time-to-event efficacy data (OS, PFS, etc.) presented. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cartilage organoids bridging bench to bedside: A steroid-free strategy for early osteoarthritis repair. PMID 41560786 · Mater Today Bio · 2026-Feb The record does not meet the fundamental eligibility criterion of being an oncology study. It is a trial for osteoarthritis, not a human malignant neoplasm. Therefore, it is excluded regardless of other criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women. PMID 41560336 · Clin Transl Sci · 2026-Feb The record describes a pharmacokinetic/bioavailability study in healthy volunteers, not a Phase III/IIIb or Phase II/III randomized efficacy trial with a time-to-event endpoint in cancer patients. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. PMID 41548565 · Lancet Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sevoflurane's inhibitory effect on postoperative colorectal cancer cell proliferation. PMID 41546564 · Pak J Pharm Sci · 2026-Feb The record meets criteria for oncology, human subjects, and randomization, but fails on phase (not Phase III/IIIb or definitive Phase II/III), primary endpoint (no time-to-event efficacy endpoint), and drug intervention (anesthetic, not oncology drug). The report is an original result but for a non-eligible study type. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study. PMID 41545648 · Clin Drug Investig · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic Model. PMID 41543367 · CPT Pharmacometrics Syst Pharmacol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. PMID 41540105 · Nat Med · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial. PMID 41539318 · Lancet Oncol · 2026-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Instructed increase in fear activation during exposure exercises does not enhance treatment effects of cognitive behavioral therapy for panic disorder and agoraphobia. PMID 41539132 · Behav Res Ther · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in patients with refractory oral lichen planus: A multicenter, pragmatic, randomized controlled trial. PMID 41539096 · Phytomedicine · 2026-Feb 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
B
|
仅广召回影子组 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Standardized patient coaching improves therapy persistence in patients with hormone receptor-positive, HER2-negative advanced/metastatic breast cancer treated with abemaciclib. PMID 41534416 · Breast · 2026-Feb Study is randomized and reports a time-to-event endpoint (TTD) for a drug (abemaciclib) in oncology. However, the primary endpoint is adherence persistence (PR24), and the study's intervention is patient coaching, not a drug itself. The report does not explicitly confirm Phase III/IIIb or Phase II/III status, which is required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with Immunotherapy. PMID 41530040 · Clin Genitourin Cancer · 2026-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers. PMID 41529317 · Clin Oncol (R Coll Radiol) · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). PMID 41526617 · Leukemia · 2026-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 2 Panel · risk unclear |
| Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat. PMID 41526614 · Leukemia · 2026-Feb The record describes a subgroup/biomarker analysis of a Phase 3 randomized trial. While the study is oncologic, human, randomized, and drug-interventional, the reported endpoint (RBC-TI duration, clonal burden) is not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis as required by the adjudication criteria. Therefore, it is not eligible for the KM digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis. PMID 41520595 · Lung Cancer · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial. PMID 41520567 · Gynecol Oncol · 2026-Feb The report is an eligible Phase III randomized trial in oncology with time-to-event endpoints, but it lacks a drug-containing intervention (it compares surgical procedures). Therefore, it does not meet all inclusion criteria. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. PMID 41519141 · Lancet Oncol · 2026-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Chewing gum versus heat therapy for postoperative recovery in patients undergoing gynecologic oncology surgery: A randomized controlled trial. PMID 41518771 · Eur J Oncol Nurs · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sentinel node mapping with carbon nanoparticles versus lymphadenectomy in early cervical cancer. PMID 41512771 · Int J Gynecol Cancer · 2026-Feb The trial is a randomized oncology study with a time-to-event efficacy endpoint, but it does not meet the required drug intervention criterion. The intervention is a surgical technique and a diagnostic mapping agent (carbon nanoparticles), which is not considered a systemic drug therapy for the purposes of this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Scoping Review Focused on Cooperative Group Involvement in Surgical Randomized Controlled Trials. PMID 41512694 · J Surg Res · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain. PMID 41503019 · AJOG Glob Rep · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of highly purified ethyl icosapentate soft capsules (MND-21) for the treatment of severe hypertriglyceridemia: A 12-week, multi-center, placebo-controlled, randomized, double-blind, phase III clinical trial in China. PMID 41500861 · J Clin Lipidol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials. PMID 41500083 · Lung Cancer · 2026-Feb The record is a biomarker analysis (subgroup) from two randomized trials (OAK and POPLAR). While the underlying trials are likely Phase III, the phase is not explicitly established in the provided metadata. More critically, this is not the original formal result report of a Phase III/IIIb or Phase II/III trial; it is a secondary, exploratory, or post-hoc analysis focusing on biomarker prognostication and predictive value. The original primary or key secondary time-to-event efficacy endpoint report (e.g., OS, PFS) for the drug intervention (atezolizumab vs. chemotherapy) is not the subject of this paper. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial. PMID 41496424 · Breast · 2026-Feb The abstract describes a biomarker (HER2/CEP17 ratio) analysis from the parent Phase III NeoALTTO trial, which is a sub-study focusing on predictive value for pCR and EFS. While the parent trial is eligible, this specific report is a pre-planned subgroup/biomarker analysis, not the primary or definitive report of the trial's main efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Post-operative pain after laparoscopy in gynecologic surgery: randomized trial on peritoneal gas drainage. PMID 41485402 · Int J Gynecol Cancer · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial. PMID 41478264 · Oral Oncol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Iodine125 grain isotope detection compared to standard metal guide detection for breast cancers: The IODINE BREAST, a randomised, non-inferiority trial. PMID 41477927 · Eur J Surg Oncol · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1/-2 and ANCHOR-1/-2. PMID 41461999 · Adv Ther · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pesco-Vegetarian Food Components Promote Colonocyte Ferroptosis in Preclinical Mouse Models and a Randomized Crossover Trial in Healthy Human Adults. PMID 41461276 · J Nutr · 2026-Feb The study is an original randomized controlled trial, but it fails multiple key eligibility criteria: it is not a Phase III or Phase II/III trial, the intervention is not a drug (it is a dietary supplement), and the outcome is not a time-to-event efficacy endpoint. Therefore, it is excluded. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| MARGIN: Randomized Trial of Arterial CT Portography Versus Standard Imaging Guidance for Percutaneous Thermal Ablation of Colorectal Liver Metastases. PMID 41457158 · Cardiovasc Intervent Radiol · 2026-Feb This is a protocol manuscript for a randomized trial. The primary endpoint is complete ablation at 3 months (a radiological response measure), not a time-to-event endpoint like OS, PFS, etc. The intervention is procedural (imaging guidance for ablation), not a drug-containing intervention. The phase is not explicitly stated as Phase III or II/III. As a protocol without results, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Datasheet for Age-Related Eye Disease Study 2 on the Database of Genotypes and Phenotypes. PMID 41450867 · Ophthalmol Sci · 2026-Feb The record describes a dataset from the AREDS2 trial, which is an oncology-excluded non-malignant-neoplasm study. It is a Phase III randomized trial but evaluates nutritional supplements for age-related macular degeneration, not a drug intervention for cancer, and lacks time-to-event efficacy endpoints relevant to oncology. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of low-sodium oxybate on diary-based sleep time in a clinical study in adults with idiopathic hypersomnia. PMID 41442817 · Sleep Med · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN. PMID 41442024 · Adv Ther · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial. PMID 41429128 · Lancet Oncol · 2026-Feb The trial compares two imaging modalities (FET-PET vs CE-T1MRI) for target volume delineation in re-irradiation, not a drug intervention. The phase is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of adding immune checkpoint inhibitors to standard therapies in non-small cell lung cancer: A systematic review of efficacy outcomes. PMID 41423066 · Crit Rev Oncol Hematol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. PMID 41422812 · Lancet Diabetes Endocrinol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Surgical timing in advanced ovarian cancer during the TRUST trial era: A systematic review, meta-analysis and study-level meta-regression of randomized controlled trials. PMID 41420991 · Eur J Surg Oncol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial. PMID 41418627 · Int J Gynecol Cancer · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration. PMID 41413355 · Eye (Lond) · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review. PMID 41413320 · Dermatol Ther (Heidelb) · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis. PMID 41412311 · Crit Rev Oncol Hematol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia. PMID 41406403 · J Clin Oncol · 2026-Feb The trial is a Phase III randomized trial in an oncology population, but it is ineligible because the primary endpoint is infection rate (a binary outcome), not a time-to-event efficacy endpoint, and the intervention is a dietary strategy, not a drug-containing intervention. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β. PMID 41405367 · Adv Sci (Weinh) · 2026-Feb The study is a Phase III randomized trial in oncology with a drug intervention, but its primary reported outcome is pathological complete response (pCR) and correlative biomarker analysis of A20 expression. No time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or its statistical representation (e.g., Kaplan-Meier curves, HR) is reported or signaled in the title or abstract. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. In press. https://doi.org/10.1016/j.annonc.2025.09.017. PMID 41402160 · Eur Urol Oncol · 2026-Feb The record is a letter to the editor (Re:) commenting on a primary trial report (ALBAN/GETUG-AFU 37) in press. It is not the original result report of the randomized trial. While it describes the trial's design (Phase 3, randomized, drug intervention), it does not provide the primary efficacy results or time-to-event endpoints (Kaplan-Meier, HR) required for eligibility. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. PMID 41393360 · JAAD Int · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial. PMID 41392465 · Tumori · 2026-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |